BRPI0409969A - composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto - Google Patents

composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto

Info

Publication number
BRPI0409969A
BRPI0409969A BRPI0409969-9A BRPI0409969A BRPI0409969A BR PI0409969 A BRPI0409969 A BR PI0409969A BR PI0409969 A BRPI0409969 A BR PI0409969A BR PI0409969 A BRPI0409969 A BR PI0409969A
Authority
BR
Brazil
Prior art keywords
compound
preparing
pharmaceutical composition
compost
alzheimer
Prior art date
Application number
BRPI0409969-9A
Other languages
English (en)
Inventor
Kevin Dinnell
Timothy Harrison
Alan John Nadin
Andrew Pate Owens
Duncan Edward Shaw
Brian John Williams
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0311341A external-priority patent/GB0311341D0/en
Priority claimed from GB0327055A external-priority patent/GB0327055D0/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of BRPI0409969A publication Critical patent/BRPI0409969A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, E, PROCESSO PARA PREPARAR UM COMPOSTO". Os compostos de Fórmula (I) inibem o processamento de APP pela gama-secretase e, em conseqüência, são úteis no tratamento ou prevenção da mal de Alzheimer.
BRPI0409969-9A 2003-05-16 2004-05-07 composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto BRPI0409969A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0311341A GB0311341D0 (en) 2003-05-16 2003-05-16 Therapeutic agents
GB0327055A GB0327055D0 (en) 2003-11-20 2003-11-20 Therapeutic agents
PCT/GB2004/002013 WO2004101539A1 (en) 2003-05-16 2004-05-07 Cyclic sulfonamides for inhibition of gamma-secretase

Publications (1)

Publication Number Publication Date
BRPI0409969A true BRPI0409969A (pt) 2006-04-25

Family

ID=33420897

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409969-9A BRPI0409969A (pt) 2003-05-16 2004-05-07 composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto

Country Status (16)

Country Link
US (3) US7410964B2 (pt)
EP (2) EP1638951B1 (pt)
JP (1) JP4818114B2 (pt)
KR (1) KR20060013404A (pt)
AT (1) ATE386028T1 (pt)
AU (1) AU2004238607B2 (pt)
BR (1) BRPI0409969A (pt)
CA (1) CA2525841C (pt)
DE (1) DE602004011767T2 (pt)
IL (1) IL171977A (pt)
IS (1) IS8058A (pt)
MX (1) MXPA05012323A (pt)
NO (1) NO20055979L (pt)
NZ (1) NZ542797A (pt)
RU (1) RU2334743C2 (pt)
WO (2) WO2004101539A1 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0108591D0 (en) * 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
GB0120347D0 (en) 2001-08-21 2001-10-17 Merck Sharp & Dohme Therapeutic agents
GB0223039D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
KR20060013404A (ko) * 2003-05-16 2006-02-09 머크 샤프 앤드 돔 리미티드 γ-세크레타제 억제용 사이클릭 설폰아미드
ATE523199T1 (de) 2004-11-02 2011-09-15 Univ Northwestern Pyridazinverbindungen und verfahren
US20090306058A1 (en) * 2005-05-17 2009-12-10 Huw David Lewis Sulphone Derivatives for Treatment of Cancer
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
GB0512049D0 (en) * 2005-06-14 2005-07-20 Merck Sharp & Dohme Chemical process
AR059075A1 (es) 2006-01-20 2008-03-12 Schering Corp Bencesulfonil - cromano , tiocromano tetrahidronaftaleno e inhibidores de gamma secretasa relacionados
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
EP2435416B1 (en) * 2007-07-05 2016-03-30 Merck Sharp & Dohme Corp. Tetrahydropyranochromene gamma secretase inhibitors
US8618123B2 (en) * 2007-07-17 2013-12-31 Merck Sharp & Dohme Corp. Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
US20110263580A1 (en) * 2008-12-11 2011-10-27 Thomas Miller Method for treating alzheimer's disease and related conditions
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
JP2013518094A (ja) * 2010-01-29 2013-05-20 ファイザー・インク γ−セクレターゼモジュレーターとしてのアミノシクロヘキサンおよびアミノテトラヒドロピランならびに関連化合物
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
SMT201700595T1 (it) 2012-11-28 2018-03-08 Merck Sharp & Dohme Composizioni e metodi per trattare il cancro
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP4076459B1 (en) 2019-12-17 2026-04-29 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP4076460B1 (en) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer
ES3022307T3 (en) 2019-12-17 2025-05-28 Merck Sharp & Dohme Llc Prmt5 inhibitors
ES3074517T3 (en) 2019-12-17 2026-07-21 Merck Sharp & Dohme Llc 4-(3,4-dihydroisoquinolin-2(1h)-yl)-3-hydroxypiperidine derivatives as prmt5 inhibitors for the treatment of cancer and sickle cell disease
WO2022015670A1 (en) * 2020-07-14 2022-01-20 Nikang Therapeutics, Inc. Pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cyclin-dependent kinase 2 inhibitors
CN120225528A (zh) 2022-09-02 2025-06-27 默沙东有限责任公司 依喜替康衍生的拓扑异构酶-1抑制剂药物组合物及其用途
KR20250079227A (ko) 2022-10-25 2025-06-04 머크 샤프 앤드 돔 엘엘씨 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도
KR20250116773A (ko) 2022-12-14 2025-08-01 머크 샤프 앤드 돔 엘엘씨 아우리스타틴 링커-페이로드, 제약 조성물, 및 그의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2833776A (en) * 1958-05-06 Aryl-substituted psperidylpropanols
US3992536A (en) * 1972-11-11 1976-11-16 Boehringer Ingelheim Gmbh Pharmaceutical compositions containing a 1-phenyl-2,2,4,4-C1 -C2 alkyl-3-[4-phenyl of pyridyl)-piperazino]-cyclobutanol-(1) and method of use
US3869434A (en) * 1973-11-19 1975-03-04 Phillips Petroleum Co Soluble arylene sulfide polymers
DE2528285A1 (de) * 1975-06-25 1977-01-20 Basf Ag Verfahren zur herstellung von 1,2,4-dihydrotriazin-4-oxid-spiro- (3,1')- eckige klammer auf oximino- (2')-cycloalkanen eckige klammer zu
FR2528433A1 (fr) * 1982-06-15 1983-12-16 Provesan Sa Nouveaux derives d'oxazinobenzothiazine-6,6-dioxyde, leur preparation et leur application en tant que medicaments
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE4035961A1 (de) * 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU757693B2 (en) * 1997-07-16 2003-03-06 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
CN1348442A (zh) 1999-02-26 2002-05-08 默克公司 新的磺胺化合物及其应用
JP2003528076A (ja) * 2000-03-20 2003-09-24 メルク シャープ エンド ドーム リミテッド スルホンアミド置換架橋ビシクロアルキル誘導体
FR2812291B1 (fr) * 2000-07-28 2002-12-13 Adir Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE60112957T2 (de) 2000-11-02 2006-05-18 Merck Sharp & Dohme Ltd., Hoddesdon Sulfamide als gamma-secretase-inhibitoren
GB0108592D0 (en) * 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
GB0108591D0 (en) 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
US7399775B2 (en) 2001-12-27 2008-07-15 Daiichi Pharmaceutical Co., Ltd. β-amyloid protein production/secretion inhibitor
KR20060013404A (ko) * 2003-05-16 2006-02-09 머크 샤프 앤드 돔 리미티드 γ-세크레타제 억제용 사이클릭 설폰아미드

Also Published As

Publication number Publication date
EP1644346A1 (en) 2006-04-12
US7410964B2 (en) 2008-08-12
KR20060013404A (ko) 2006-02-09
DE602004011767D1 (de) 2008-03-27
ATE386028T1 (de) 2008-03-15
RU2334743C2 (ru) 2008-09-27
CA2525841C (en) 2012-10-16
IL171977A0 (en) 2006-04-10
NO20055979L (no) 2006-02-15
JP4818114B2 (ja) 2011-11-16
US20040230054A1 (en) 2004-11-18
US20060281737A1 (en) 2006-12-14
AU2004238607A1 (en) 2004-11-25
DE602004011767T2 (de) 2009-02-19
IS8058A (is) 2005-09-30
WO2004101539A1 (en) 2004-11-25
EP1638951A1 (en) 2006-03-29
EP1638951B1 (en) 2008-02-13
US20080045515A1 (en) 2008-02-21
AU2004238607B2 (en) 2010-05-27
MXPA05012323A (es) 2006-01-30
WO2004101538A1 (en) 2004-11-25
CA2525841A1 (en) 2004-11-25
US7342009B2 (en) 2008-03-11
IL171977A (en) 2010-12-30
JP2006528961A (ja) 2006-12-28
NZ542797A (en) 2007-12-21
RU2005139398A (ru) 2006-04-10

Similar Documents

Publication Publication Date Title
ATE368031T1 (de) Neue gamma secretase inhibitoren
BR0309546A (pt) Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
ATE464287T1 (de) Cyclohexyl-sulphone als gamma-sekretase- inhibitoren
MXPA05012323A (es) Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
DE60329533D1 (de) Cyclische sulfamide zur inhibierung von gamma-sekretase
BRPI0411582A (pt) substáncias terapêuticas contendo boro hidroliticamente resistentes e método de uso
BRPI0415398A (pt) composto, composição farmacêutica, processo para a preparação da mesma, uso de um composto, método de tratamento de cáncer, e, processo para preparação de um composto
BR0200782A (pt) Compostos para o tratamento da isquemia
CY1111050T1 (el) Φωσφονικα, μονοφωσφοναμιδικα, διφωσφοναμιδικα για την αγωγη των ιϊκων παθησεων
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
ATE302753T1 (de) Sulfamide als gamma-secretase-inhibitoren
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
PT1200412E (pt) Agentes anti-proliferativos de imidazole
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BRPI0412851A (pt) benzamidazóis de n-metila-substituìdos
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
BRPI0409523A (pt) método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
BRPI0416287A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização
EE200400031A (et) Biokeemiliste ühendite kompositsioon, selle kasutamine maatriks-metalloproteinaaside pärssimiseks ning seda sisaldav ravimpreparaat
NO20054787D0 (no) Indenderivater som farmasotiske midler
BR0211635A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de um indivìduo sofrendo de ou propenso à doença de alzheimer
BR0309753A (pt) Processo para a preparação de derivados de 6-alquilideno penem
BR0312470A (pt) Composto, uso do mesmo, composição farmacêutica, método de tratar e/ou prevenir câncer, e, processo para preparar o composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.